|Day Low/High||50.66 / 53.17|
|52 Wk Low/High||49.03 / 77.12|
Posting results 'not as a bad as we thought' has become a successful strategy. It worked for Bristol.
Stock losses accelerate heading into the market close on Thursday after defensive names slip on a spike in Treasury yields.
Bristol-Meyers (bmy) CEO Giovanni Caforio remains confident of the direction the business is moving.
Stocks hold mixed on Thursday afternoon as Bristol-Myers Squibb and Celgene push health care higher, while defensive names slip on a spike in Treasury yields.
Bristol-Myers, ServiceNow and Kimberly-Clark have posted major third quarter earnings surprises, but they are not the only one, says Jim Cramer.
Bristol-Myers (BMY) posted better-than-expected 2016 third-quarter results and raised its earnings guidance for the year.
The long-term story remains in question due to issues with the company's pivotal first-line lung cancer study.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2016 which were highlighted by strong sales and operating performance, and continued growth for key products including Opdivo ...
The pharmaceutical giant has reason to be optimistic about its earnings release tomorrow.
Jim Cramer likes YUM; says STZ is more appetizing than MNST
Index funds are great, Jim Cramer says, but he encourages investors to do some smart stock picking.
Bristol-Myers (BMY) will report financial results for the 2016 third quarter before Thursday's opening bell.
Bristol-Myers Squibb Company (NYSE:BMY) today announced new results from CheckMate -205, a multi-cohort, single-arm, Phase 2 trial evaluating Opdivo (nivolumab) in patients with classical Hodgkin lymphoma (cHL).
Bristol-Myers Squibb's (NYSE:BMY) Coast 2 Coast 4 Cancer has raised more than $1,050,000 to support Stand Up To Cancer's collaborative cancer research programs.
For the week of October 24, investors await quarterly results from a slew of major companies, including Apple, along with the first estimate of third quarter GDP.
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
Here's your 'silver linings playbook' for what promises to be a nerve-wracking week of unpredictable politics, mixed corporate earnings and volatile energy prices.
Flood of earnings, data and reports restrains the market, with no help from Wednesday's debate. We added to one of our portfolio positions.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016.
The drug titan reports Tuesday. Will a Dec. 24 cancer drug approval be an early Christmas gift?
Vale may be worth following again. Bristol-Myers? Not so much.
Cramer says P&G is a good choice and is disappointed by Bristol-Myers Squibb.
A malaise has once again befallen America, Cramer says.
Today the Bristol-Myers Squibb Foundation joins the White House Cancer Moonshot initiative through its commitment to addressing health disparities in cancer care.
We took advantage of several down days during the week to add to a recently added position.